Abstract OT-09-05: A randomized, pre-surgical study to investigate the biological effects of AZD9833 doses in women with ER-positive HER2-negative primary breast cancer (SERENA-3)

• Published in: Cancer research (Chicago, Ill.) Vol. 81; no. 4_Supplement; p. OT-09-05
• Main Authors: Robertson, John FR, Moppett, Iain, Rocha, Juan Enrique Bargalló, Dzagnidze, Giorgi, Harding, Joanna, Klinowska, Teresa, Mather, Richard, Mathewson, Alastair, Maudsley, Rhiannon, Morrow, Christopher J, Saunders, Andrew, Sykes, Andy, Zhang, Li, Lindemann, Justin PO
• Format: Journal Article
• Language: English
• Published: 15.02.2021

Abstract Background AZD9833 is an orally bioavailable selective estrogen receptor (ER) antagonist and degrader (SERD) that has shown anti-tumor efficacy in a range of preclinical breast cancer models. SERENA-1, an ongoing first-in-human study assessing AZD9833 as a monotherapy and in combination wit...